VSIG4 Is Dispensable for Tumor Growth and Metastasis in Murine Colorectal and Breast Cancer Models
Authors:
- Els LebeggeELEls Lebegge
- Neema Ahishakiye JumapiliNJNeema Ahishakiye Jumapili
- Jolien Van CraenenbroeckJCJolien Van Craenenbroeck
- Daliya KanchevaDKDaliya Kancheva
- Máté KissMKMáté Kiss
- Romina Mora BarthelmessRBRomina Mora Barthelmess
- Ahmed E. I. HamoudaAHAhmed E. I. Hamouda
- Yvon ElkrimYEYvon Elkrim
- Geert RaesGRGeert Raes
- Éva HadadiÉHÉva Hadadi
- Damya LaouiDLDamya Laoui
- Jo A. Van GinderachterJGJo A. Van Ginderachter
Open Access
Abstract
Background: Tumor-associated macrophages (TAMs) are important contributors to tumor progression and metastasis. Therefore, the identification of molecules that mediate these cells’ tumor-promoting functions is highly warranted. VSIG4 has been proposed as a macrophage immune checkpoint. Hence, we aim to investigate this marker in preclinical models. Methods: Publicly available scRNAseq datasets of human colorectal (CRC) and triple-negative breast (TNBC) carcinomas and their murine counterparts were reanalyzed to investigate the expression of VSIG4 in the different TAM populations. Moreover, tumors were grown in Vsig4-deficient mice to evaluate the effect on primary tumor characteristics. Finally, since liver Kupffer cells and large peritoneal macrophages are at least partly VSIG4-high, and are implicated in metastasis to those organs, the dissemination of CRC cancer cells to those sites was assessed in the Vsig4-deficient mice. Results: We demonstrate that VSIG4 expression in human CRC and TNBC is mostly restricted to TAMs, and that its expression correlates with a worse prognosis. However, a striking finding was that no Vsig4 mRNA nor protein could be detected in the microenvironment of primary CRC and TNBC murine tumors, resulting in a similar tumor growth in wild type versus Vsig4-deficient mice. Moreover, no major differences were observed in metastatic tumor load in the liver and peritoneal cavity, apart from a reduced metastasis to the omentum in Vsig4-deficient animals. Conclusions: Murine cancer models are not suitable to investigate the role of VSIG4 in primary tumors and VSIG4 deficiency did not alter liver nor peritoneal cavity metastasis in murine models, with the exception of the omentum.Keywords
Funding Information
- Kom op tegen Kanker
- Fonds Wetenschappelijk Onderzoek (1S67419N)
- FWO-SBO project MATATUM (S000218N)
This publication has 51 references indexed in Scilit:
- VSIG4‐Expressing Macrophages Contribute to Antiparasitic and Antimetastatic Responses in the Peritoneal CavityEuropean Journal of Immunology, 2025
- The immunosuppressive role of VSIG4 in colorectal cancer and its interaction with the tumor microenvironmentDiscover Oncology, 2025
- How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translationInternational Journal of Cancer, 2023
- VSIG4/CRIg directly regulates early CD8+ T cell activation through its counter-receptor in a narrow windowBiochemical and Biophysical Research Communications, 2022
- Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III–IV epithelial ovarian cancerInternational Journal of Clinical Oncology, 2021
- Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancerGastric Cancer, 2020
- Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver PathogenesisMolecular Imaging and Biology, 2016
- Generation of Single Domain Antibody Fragments Derived from Camelids and Generation of Manifold Constructs2012
- Regulation of CRIg Expression and Phagocytosis in Human Macrophages by Arachidonate, Dexamethasone, and CytokinesThe American Journal of Pathology, 2011
- Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liverHepatology, 1996